source
- Blackstone puts $250M into Anagram to tackle cystic fibrosis complicationBlackstone Life Sciences, fresh off one of the largest private investment funds in industry history, is putting $250 million to work on a little-known biotech seeking to drastically reduce the numb…Endpoints · 4mo ago↗ source
- FDA Completes Type A Meeting Following CRL for Tabelecleucel in EBV+ R/R Post-Transplant Lymphoproliferative DiseaseThe FDA and Atara Biotherapeutics completed a Type A meeting to discuss the CRL for tabelecleucel in post-transplant lymphoproliferative disease.onclive · 4mo ago↗ source
- ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing StudiesExperts spotlight the triple-negative breast cancer abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.